Abstract：Objective To investigate the therapeutic effect of Recombinant Human Thrombopoietin (rhTPO) and methylprednisolone in the treatment of adult primary immune thrombocytopenia (ITP).Methods Eighty patients with ITP admitted to Suzhou Kowloon Hospital Affiliated to Shanghai Jiaotong University Medical School from March 2017 to December 2019 were selected as the research subjects.They were divided into an observation group (n=40) and a control group (n=40) according to the random number table method.Patients in the two groups received conventional treatment.Patients in the control group were additionally treated with Methylprednisolone on the basis of conventional therapy,and patients in the observation group were additionally treated with rhTPO on the basis of the control group.The changes in platelet count (PTL) and immune function of the two groups before and after treatment were compared.The occurrence of adverse reactions of the two groups was analyzed.Results The PTL levels of the two groups after treatment were higher than those before,and the differences were statistically significant (P＜0.05).The PTL level in the observation group after treatment was higher than that of the control group,and the difference was statistically significant(P＜0.05).The CD3+,CD4+,CD4+/CD8+values in the two groups after treatment were higher than those before treatment,and the differences were statistically significant (P＜0.05).The CD3+,CD4+,CD4+/CD8+ values of the observation group after treatment were higher than those of the control group,and the differences were statistically significant (P＜0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion The combination of rhTPO and methylprednisolone in the treatment of patients with ITP has a remarkable clinical effect.It can effectively increase the PTL of patients and improve the immune function with few adverse reactions and a certain degree of safety.
京公网安备 11010502046607号